Johnson & Johnson (NYSE:JNJ - Get Free Report)'s stock price was down 2.1% during trading on Thursday. The stock traded as low as $264.68 and last traded at $267.02. 9,825,683 shares changed hands during trading, an increase of 24% from the average session volume of 7,955,000 shares. The stock had previously closed at $272.70.
Johnson & Johnson News Summary
Investors following JNJ have been watching these news items:
Analyst Ratings Changes
Several equities research analysts have issued reports on JNJ shares. Wells Fargo & Company boosted their price target on shares of Johnson & Johnson from $275.00 to $287.00 and gave the company an "overweight" rating in a report on Friday, October 16th. UBS Group set a $270.00 price target on Johnson & Johnson in a research report on Wednesday, October 14th. Sanford C. Bernstein set a $270.00 price objective on shares of Johnson & Johnson in a research report on Thursday, October 15th. Bank of America reiterated a "neutral" rating and issued a $278.00 price objective on shares of Johnson & Johnson in a research report on Tuesday, September 29th. Finally, Argus set a $300.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $275.92.
Read Our Latest Research Report on JNJ
Johnson & Johnson Price Performance
The stock has a market cap of $642.80 billion, a price-to-earnings ratio of 40.46, a P/E/G ratio of 2.75 and a beta of 0.22. The company has a 50 day simple moving average of $267.42 and a 200-day simple moving average of $250.61. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 0.44.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, topping analysts' consensus estimates of $2.53 by $0.06. The firm had revenue of $25.40 billion during the quarter, compared to the consensus estimate of $25.38 billion. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The business's revenue was up 5.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Research analysts expect that Johnson & Johnson will post 11.12 EPS for the current year.
Johnson & Johnson Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be given a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a yield of 2.0%. Johnson & Johnson's dividend payout ratio (DPR) is 81.21%.
Insider Buying and Selling at Johnson & Johnson
In other Johnson & Johnson news, EVP Timothy Schmid sold 33,597 shares of the business's stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the sale, the executive vice president directly owned 25,447 shares of the company's stock, valued at $6,991,308.78. The trade was a 56.90% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Elizabeth Forminard sold 13,072 shares of the firm's stock in a transaction dated Thursday, November 12th. The shares were sold at an average price of $284.39, for a total value of $3,717,546.08. Following the completion of the transaction, the executive vice president owned 16,994 shares of the company's stock, valued at $4,832,923.66. The trade was a 43.48% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.16% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the stock. Heartland Bank & Trust Co increased its position in shares of Johnson & Johnson by 0.8% during the 3rd quarter. Heartland Bank & Trust Co now owns 15,295 shares of the company's stock worth $4,049,000 after purchasing an additional 118 shares during the last quarter. Kensington Investment Counsel LLC boosted its holdings in shares of Johnson & Johnson by 3.6% in the 3rd quarter. Kensington Investment Counsel LLC now owns 26,582 shares of the company's stock valued at $7,037,000 after buying an additional 919 shares during the last quarter. Robinhood Markets Inc. acquired a new stake in shares of Johnson & Johnson in the 3rd quarter valued at approximately $282,000. Innovator Capital Management LLC bought a new position in shares of Johnson & Johnson in the third quarter valued at $35,454,000. Finally, Claris Financial LLC bought a new position in shares of Johnson & Johnson in the third quarter valued at $1,245,000. 69.55% of the stock is currently owned by institutional investors.
Johnson & Johnson Company Profile
(
Get Free Report)
Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.